- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Natco Pharma Limited — Updates, 03-02-2026: Press Release
03-02-2026 | 02:50 pm
03-02-2026 | 02:50 pm
NATCO Pharma received tentative US FDA approval for generic Erdafitinib (Balversa®). This targets a $60 million US market for treating urothelial carcinoma. A key strategic win expanding its US generic portfolio.
No comments yet. Be the first to comment!